PREFACE:
- In platinum sensitive disease: patients should be considered for doublet therapy consisting of carboplatin plus either a taxane or gemcitabine or DOXOrubicin pegylated liposomal (e.g., GOOVCATR, GOOVCAD, GOOVCA, GOOVPLDC)
- In platinum resistant disease (i.e., cancer progresses within six months of completing a platinum-containing treatment protocol): patients will ideally receive single agent carboplatin, as it is the least toxic and most convenient choice of the equally efficacious agents available (i.e., GOOVCARB)
- In platinum refractory disease (i.e., cancer progresses while being treated with a platinum) choose between available agents based upon toxicity profile and convenience of dosing regimen. Options include: GOOVTOP, GOOLDOX, GOOVGEM, GOOVETO, GOOVVIN, GOOVTAJ, GOOVDOC.
- Patients who will not benefit from further therapy after second or subsequent rounds of chemotherapy can be identified by the following formula: “day 1 of treatment N to day of progression on treatment N+1 is less than or equal to 6 months.” They should be offered symptomatic management or investigational protocols.

ELIGIBILITY:
- Platinum refractory ovarian, primary peritoneal or Fallopian tube carcinoma
- Platinum resistant ovarian, primary peritoneal or Fallopian tube carcinoma in cases where patient-specific concerns dissuade the clinician from selecting single-agent carboplatin
- Platinum sensitive ovarian, primary peritoneal or Fallopian tube carcinoma in cases where actual or potential toxicity precludes the use of carboplatin or cisplatin alone or in combination with a taxane or gemcitabine.
- Adequate hematologic, liver and cardiac function
- PS ECOG 3 or better

TESTS:
- Mandatory Baseline tests: CBC, including differential and platelets, creatinine
- Suggested Baseline tests: appropriate tumour markers and imaging study
- In Cycle 1 and in any Cycle in which a dose change has been made: Before treatment on days 1, 8, and 15: CBC, including differential and platelets
- In Cycle 2 and subsequent cycles when no dose change has been made: Before treatment on day 1 only: CBC, including differential and platelets
- Appropriate tumour markers and imaging studies should be repeated as necessary

PREMEDICATIONS:
- Antiemetic protocol for chemotherapy with low to low-moderate emetogenicity (see SCNAUSEA)
**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>gemcitabine</td>
<td>800 mg/m² on day 1, 8, and 15</td>
<td>IV in 250 mL NS over 30 minutes</td>
</tr>
</tbody>
</table>

Repeat every 28 days **until disease progression** (usual treatment 9 cycles).

**DOSE MODIFICATIONS:**

1. **Hematology:** on day 1 in any cycle; and on day 1, 8 and 15 in cycle 1 and in all cycles in which a dose change has been made

<table>
<thead>
<tr>
<th>ANC (x 10⁹/L)</th>
<th>Platelets (x 10⁹/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.0</td>
<td>and greater than or equal to 100</td>
<td>100%</td>
</tr>
</tbody>
</table>

2. **Febrile Neutropenia:** decrease subsequent doses to 700 mg/m². If a recurrence of febrile neutropenia occurs despite dose reduction to 700 mg/m²: either (i) discontinue gemcitabine if regimen had been day 1 and 8 only, or day 1 & 15 only; or, (ii) change to day 1 and 8 only, or day 1 and 15 only, if regimen had been day 1, 8 and 15.

3. **Pneumonitis:** discontinue gemcitabine if pneumonitis occurs

4. **Non–Hematologic Toxicities:** may include
   - Mucositis
   - Transient truncal rash
   - Fatigue
   - For Grade 3 toxicity, delay treatment until resolution of symptoms, then resume at 700 mg/m². If dose already reduced, switch to day 1 and 8 only or day 1 and 15 only. If Grade 3 toxicity persists, discontinue gemcitabine.
   - For Grade 4 toxicity, discontinue treatment.
   - Doses reduced for toxicity should not be re-escalated.
PRECAUTIONS:
1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively.
2. **Renal Dysfunction**: Irreversible renal failure associated with hemolytic uremic syndrome may occur (rare). Use caution with pre-existing renal dysfunction.
3. **Pulmonary Toxicity**: Acute shortness of breath may occur. Discontinue treatment if drug-induced pneumonitis is suspected.
4. **Fever and Flu-like Symptoms**: may commonly occur (fever 37%, flu-like symptoms 19%). Use acetaminophen as necessary for comfort.
5. **Drug Interaction – warfarin**: gemcitabine may cause increased anticoagulant effect of warfarin. Monitor INR carefully during and for 1 to 2 months after gemcitabine therapy; adjust warfarin dose as necessary.

Call Dr. Anna Tinker or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.